 |
|
Corticosteroid Therapy in Pulmonary Sarcoidosis
A Systematic Review
Shanthi Paramothayan, PhD,MRCP;
Paul W. Jones, PhD,FRCP
JAMA. 2002;287:1301-1307.
Context Corticosteroids are used in pulmonary sarcoidosis to reduce symptoms and minimize long-term damage. Spontaneous recovery is a common feature. Both the decision to initiate therapy and the treatment response may be influenced by disease severity, so trials need to use a randomized controlled design.
Objective To assess the effect of oral and inhaled corticosteroids on chest radiograph results, symptoms, pulmonary function, and long-term outcome in pulmonary sarcoidosis.
Data Sources MEDLINE, EMBASE, CINAHL, and the Cochrane Controlled Trials Register were searched all years through December 2001. Bibliographies of review articles and retrieved articles were searched, and pharmaceutical companies and authors of identified trials were contacted for other studies. There was no language restriction.
Study Selection Trials were randomized and included a control group. Participants were adults with histologic evidence of pulmonary sarcoidosis. Treatments included the use of oral and inhaled corticosteroids for at least 8 weeks. The search identified 150 studies; 9 met the inclusion criteria, but only 8 provided usable data.
Data Extraction Two reviewers assessed trial quality using the Jadad score, which evaluates the quality of randomization, blinding, and reasons for withdrawal. Data were extracted and sent to primary authors for verification.
Data Synthesis In patients with stage 2 and 3 disease, oral corticosteroids improved findings on the chest radiograph after 6 to 24 months (Peto odds ratio, 2.54; 95% confidence interval [CI], 1.69-3.81; P<.001). Forced vital capacity improved with oral corticosteroids (weighted mean difference [WMD], 4.2% predicted; 95% CI, 0.4%-7.9% predicted) and diffusing capacity also improved (WMD, 5.7% predicted; 95% CI, 1.0%-10.5% predicted). In 2 small studies of inhaled corticosteroids, there was no effect on chest radiograph and inconsistent effects on lung function in one and only a small improvement in symptoms in the other. There were no data following corticosteroid withdrawal to assess any disease-modifying effect.
Conclusions Oral corticosteroids improved results on the chest radiograph following 6 to 24 months of treatment and produced a small improvement in vital capacity and diffusing capacity. Trials of inhaled corticosteroids were small and results too inconsistent to make firm conclusions concerning their efficacy. There are no data to suggest that corticosteroid therapy alters long-term disease progression.
Author Affiliations: Division of Physiological Medicine, St George's Hospital Medical School, London, England.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
March 13, 2002
JAMA. 2002;287(10):1333-1334.
EXTRACT
| FULL TEXT
Living With Sarcoidosis
JAMA. 2002;287(10):1350.
PDF
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Changes in Chest Roentgenogram of Sarcoidosis Patients During a Clinical Trial of Infliximab Therapy: Comparison of Different Methods of Evaluation
Baughman et al.
Chest 2009;136:526-535.
ABSTRACT
| FULL TEXT
Review: Therapies for interstitial lung disease: past, present and future
Kim and Meyer
Ther Adv Respir Dis 2008;2:319-338.
ABSTRACT
Interstitial lung disease guideline
Wells et al.
Thorax 2008;63:v1-v58.
FULL TEXT
Review: Treating patients with respiratory disease who smoke
Braganza et al.
Ther Adv Respir Dis 2008;2:95-107.
ABSTRACT
Six-Minute Walk Test and Health Status Assessment in Sarcoidosis
Baughman et al.
Chest 2007;132:207-213.
ABSTRACT
| FULL TEXT
A 47-year-old woman with sarcoidosis.
Weinberger
JAMA 2006;296:2133-2140.
ABSTRACT
| FULL TEXT
Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement
Baughman et al.
Am. J. Respir. Crit. Care Med. 2006;174:795-802.
ABSTRACT
| FULL TEXT
Corticosteroid treatment in sarcoidosis.
Grutters and van den Bosch
Eur Respir J 2006;28:627-636.
ABSTRACT
| FULL TEXT
Presenting characteristics as predictors of duration of treatment in sarcoidosis
Baughman et al.
QJM 2006;99:307-315.
ABSTRACT
| FULL TEXT
Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines: Report From an American College of Chest Physicians Task Force
Guyatt et al.
Chest 2006;129:174-181.
ABSTRACT
| FULL TEXT
Fungal infections as a complication of therapy for sarcoidosis
Baughman and Lower
QJM 2005;98:451-456.
ABSTRACT
| FULL TEXT
Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status
Spruit et al.
Thorax 2005;60:32-38.
ABSTRACT
| FULL TEXT
Future Directions in Sarcoidosis Research: Summary of an NHLBI Working Group
Martin et al.
Am. J. Respir. Crit. Care Med. 2004;170:567-571.
ABSTRACT
| FULL TEXT
The Sarcoidosis Health Questionnaire: A New Measure of Health-related Quality of Life
Cox et al.
Am. J. Respir. Crit. Care Med. 2003;168:323-329.
ABSTRACT
| FULL TEXT
Sarcoidosis
Thomas and Hunninghake
JAMA 2003;289:3300-3303.
FULL TEXT
|
